Todd Simpson

Todd E.
Simpson is currently Director at Shape Therapeutics, Inc. since 2024, Independent Director at Xencor, Inc. starting in 2025, and Advisor at Inovia Capital (US), Inc. since 2017.
Former roles include Director at Cascadian Therapeutics LLC, Independent Director at Aquinox Pharmaceuticals, Inc., Director at Neoleukin Therapeutics, Inc., Independent Director at Neoleukin Therapeutics, Inc. from 2014 to 2020, Director at Life Science Washington, Chief Financial Officer & Vice President at Telios Pharmaceuticals, Inc. from 1992 to 1995, Chief Financial Officer & VP-Administration at AmpliPhi Biosciences Corp.
from 1996 to 2001, CFO & VP-Finance & Administration at AmpliPhi Biosciences Corp.
from 2001 to 2005, Treasurer at Integra LifeSciences Holdings Corp.
in 1995, CFO, VP-Finance & Administration at Vericel Corp.
from 1996 to 2001, Chief Financial Officer & VP-Administration at Vericel Corp.
from 1992 to 1995, Principal at Ernst & Young LLP from 1983 to 1992, and Chief Financial Officer at Seagen, Inc. from 2005 to 2022.
Education includes undergraduate studies at Oregon State University.